Article
Advances in targeted therapies for hepatocellular carcinoma in the genomic era.
Nature reviews. Clinical oncology - 1 Jul 2015
Llovet Josep M, Villanueva Augusto, Lachenmayer Anja, Finn Richard S
Abstract excerpt
Mortality owing to liver cancer has increased in the past 20 years, and the latest estimates indicate that the global health burden of this disease will continue to grow. Most patients with hepatocellular carcinoma (HCC) are still diagnosed at intermediate or advanced disease stages, where curative approaches are often not feasible. Among the treatment options available, the molecular targeted agent sorafenib is...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.